Benken Jamie, Lichvar Alicia, Benedetti Enrico, Behnam Jessica, Kaur Arashpreet, Rahman Syeda, Nishioka Hokuto, Hubbard Colin, Benken Scott T
Department of Pharmacy Practice, 15508University of Illinois at Chicago College of Pharmacy, Chicago, IL.
UC San Diego Health, Center for Transplantation, San Diego, CA.
Prog Transplant. 2022 Apr 28:15269248221087433. doi: 10.1177/15269248221087433.
Negative outcome studies of vasopressors in kidney transplant have not focused on patient populations that are predominantly Black or Hispanic. Project The evaluation sought to investigate the independent impact of perioperative vasopressors on postoperative renal allograft function in a sample drawn from a primarily Black and Hispanic population. Retrospective, observational, single-center evaluation of patients > 18 years old who underwent kidney transplantation comparing outcomes based on vasopressor exposure. The study included 150 patients of which 60 received vasopressors. The primary outcome differed between groups with delayed graft function occurring in 17(28%) versus 11(12.2%) occurring more often in those that received perioperative vasopressors (P = 0.02). The serum creatinine at postoperative day 7 was higher (2.69 vs1.52 mg/dL, P = 0.004), postoperative day 7 eGFR was worse (27.3 vs 52.9 mL/min/1.73m2, P = 0.002) in patients who received vasopressors. Patients who received perioperative vasopressors experienced more postoperative arrhythmias (15% vs 8%, P = 0.007), insulin infusion therapy (26.7% vs 13.3%, P = 0.04), and increased hospital length of stay (6 days vs 5 days, P = 0.006). Using IPWRA, patients receiving vasopressors were more likely to experience delayed function, relative risk difference of 22% (95% CI:0.08-0.35;P = 0.002) and in multivariate logistic regression modeling, an increased odds ratio of 3.2 (95% CI:1.1-8.62;P = 0.022). The use of perioperative vasopressors was independently associated with worsened early renal allograft function including delayed graft function, increased adverse events such as postoperative arrhythmias, and longer ICU length of stay. Further investigation is needed surrounding vasopressor use in this population.
肾移植中血管升压药的负面结果研究并未聚焦于以黑人或西班牙裔为主的患者群体。项目 该评估旨在调查围手术期血管升压药对主要来自黑人和西班牙裔人群样本中术后肾移植功能的独立影响。对18岁以上接受肾移植的患者进行回顾性、观察性、单中心评估,比较基于血管升压药暴露情况的结果。该研究纳入了150名患者,其中60名接受了血管升压药治疗。两组的主要结局存在差异,移植肾功能延迟在接受围手术期血管升压药治疗的患者中发生率更高(17例[28%]对11例[12.2%],P = 0.02)。接受血管升压药治疗的患者术后第7天的血清肌酐更高(2.69对1.52 mg/dL,P = 0.004),术后第7天的估算肾小球滤过率更差(27.3对52.9 mL/min/1.73m²,P = 0.002)。接受围手术期血管升压药治疗的患者术后心律失常更多(15%对8%,P = 0.007),胰岛素输注治疗更多(26.7%对13.3%,P = 0.04),住院时间更长(6天对5天,P = 0.006)。使用逆概率加权回归调整法,接受血管升压药治疗的患者更有可能出现移植肾功能延迟,相对风险差异为22%(95%置信区间:0.08 - 0.35;P = 0.002),在多因素逻辑回归模型中,优势比增加3.2(95%置信区间:1.1 - 8.62;P = 0.022)。围手术期使用血管升压药与早期肾移植功能恶化独立相关,包括移植肾功能延迟、术后心律失常等不良事件增加以及重症监护病房住院时间延长。需要对该人群中血管升压药的使用进行进一步研究。